Overview

A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy in subjects with previously untreated extensive-stage small cell lung cancer (SCLC), increases survival.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa
Etoposide
Etoposide phosphate